LLY.F - Eli Lilly and Company
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285
United States
317 276 2000
https://www.lilly.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers—General
Employés à temps plein: 39 000
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. David A. Ricks | Chairman, CEO & Pres | 4,42M | S.O. | 1968 |
| Ms. Anat Ashkenazi | Exec. VP & CFO | 2,13M | S.O. | 1973 |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories | 2,72M | S.O. | 1974 |
| Ms. Anat Hakim J.D. | Exec. VP, Gen. Counsel & Sec. | 1,98M | S.O. | 1969 |
| Mr. Patrik Jonsson | EVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology | 1,67M | S.O. | 1967 |
| Mr. Donald A. Zakrowski | Chief Accounting Officer & VP of Fin. | S.O. | S.O. | S.O. |
| Mr. Diogo Rau | EVP & Chief Information and Digital Officer | S.O. | S.O. | S.O. |
| Mr. Alonzo Weems | EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer | S.O. | S.O. | 1971 |
| Ms. Leigh Ann Pusey | Exec. VP of Corp. Affairs & Communications | S.O. | S.O. | 1963 |
| Mr. Eric Dozier | Exec. VP of HR & Diversity | S.O. | S.O. | 1967 |
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Eli Lilly and Company en date du 1 juin 2023 est 5. Les scores principaux sont Audit : 3; Société : 5; Droits des actionnaires : 9; Compensation : 1.
